Patents by Inventor Reiner L. Gentz

Reiner L. Gentz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human genes, sequences and expression products
    Publication number: 20030208043
    Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.
    Type: Application
    Filed: June 4, 2003
    Publication date: November 6, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Paul A. Moore, Reiner L. Gentz, Hongjun Ji, Jian Ni, Jing-Shan Hu
  • Fc Receptors and polypeptides
    Publication number: 20030208054
    Abstract: The present invention relates to four novel Fc receptor-like proteins which are members of the Fc Receptor family. In particular, isolated nucleic acid molecules are provided encoding the human FcR-I, FcR-II, FcR-III, and FcR-IV proteins. FcR-I, FcR-II, FcR-III, and FcR-IV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of FcR-I, FcR-II, FcR-III, and FcR-IV activities. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: July 16, 2001
    Publication date: November 6, 2003
    Inventors: Henrik S. Olsen, Jian Ni, Marianne Murphy, Steven M. Ruben, Reiner L. Gentz
  • Galectin 11
    Publication number: 20030208044
    Abstract: The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human galectin 11 proteins. Galectin 11 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of galectin 11 activity. Also provided are diagnostic and therapeutic methods.
    Type: Application
    Filed: June 6, 2003
    Publication date: November 6, 2003
    Applicants: Human Genome Sciences, Inc., La Jolla Institute for Allergy and Immunology
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen, Fu-Tong Liu
  • T1 receptor-like ligand II and uses thereof
    Publication number: 20030198618
    Abstract: The present invention relates to a novel T1 Receptor (T1R)-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same. This invention further relates to pharmaceutical compositions and formulations comprising T1R-like ligand II. Also provided are methods of using T1R-like ligand II polynucleotides, polypeptides, antibodies or agonists/antagonists for therapeutic and diagnostic purposes. Diagnostic kits are further provided.
    Type: Application
    Filed: May 16, 2003
    Publication date: October 23, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben
  • Chemokine compositions
    Patent number: 6632425
    Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: October 14, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Yuling Li, Mark Oelkuct, Reiner L. Gentz
  • Tissue factor pathway inhibitor-3
    Publication number: 20030187200
    Abstract: The present invention relates to a novel TFPI-3 protein which is a member of the tissue factor protease inhibitor family. In particular, isolated nucleic acid molecules are provided encoding human TFPI-3 proteins. TFPI-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TFPI-3 activity. Also provided are diagnostic methods for detecting hemostasis system-related disorders and therapeutic methods for treating hemostatis system-related disorders.
    Type: Application
    Filed: June 21, 2002
    Publication date: October 2, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Tsu-An Hsu, Craig A. Rosen, Jian Ni
  • Synferon
    Publication number: 20030185797
    Abstract: The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon polypeptide, called “Synferon”. Synferon polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Synferon activity. Also provided are therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: February 3, 2003
    Publication date: October 2, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Reiner L. Gentz, Steven M. Ruben
  • Keratinocyte growth factor-2
    Publication number: 20030186904
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Application
    Filed: January 4, 2002
    Publication date: October 2, 2003
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Steven M. Ruben, Pablo Jimenez, Roxanne D. Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
    Patent number: 6623938
    Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: September 23, 2003
    Assignees: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, Vishva M. Dixit, Reiner L. Gentz, Joseph J. Kenny
  • Death domain containing receptors
    Publication number: 20030170203
    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
    Type: Application
    Filed: July 5, 2002
    Publication date: September 11, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
  • Human cystatin E polynucleotides
    Patent number: 6617132
    Abstract: Disclosed is a human CysE polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for treating osteoporosis, tumor metastases, microbial infections, viral infection, septic shock, inflammation, retinal irritation, caries, cachicia and muscle wasting. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: September 9, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Myelin oligodendrocyte glycoprotein-like protein (MOGp)
    Publication number: 20030166898
    Abstract: The present invention relates to a novel MOGp protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human MOGp protein. MOGp polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating cancer, inflammation, and multiple sclerosis (MS).
    Type: Application
    Filed: July 19, 2002
    Publication date: September 4, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Arvind Chopra, Henrik S. Olsen, Reiner L. Gentz, Steven M. Ruben
  • CD33-like protein
    Publication number: 20030166914
    Abstract: The present invention concerns a novel CD33-like protein. In particular, isolated nucleic acid molecules are provided encoding the CD33-like protein. Recombinant CD33-like polypeptides are also provided as are recombinant vectors and host cells. The invention further provides methods useful during tumor or inflammatory disease diagnosis or prognosis and therapeutic treatments targeting cells expressing CD33-like polypeptides.
    Type: Application
    Filed: April 15, 2003
    Publication date: September 4, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen
  • Leukocyte regulatory factors 1 and 2
    Publication number: 20030162956
    Abstract: The present invention relates to novel LRF-1 and LRF-2 proteins which are related to the CRISP family and a protein called “Neutrophil Inhibitory Factor (NIF)” isolated from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function. In particular, isolated nucleic acid molecules are provided encoding the human LRF-1 and LRF-2 proteins. LRF-1 and LRF-2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of LRF-1 or LRF-2 activity. Also provided are diagnostic methods for detecting immune system or other LRF-1 or LRF-2-related disorders and therapeutic methods for treating such disorders.
    Type: Application
    Filed: March 14, 2003
    Publication date: August 28, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Jing-Shan Hu, Steven M. Ruben, Reiner L. Gentz
  • Human extracellular matrix-1
    Patent number: 6610829
    Abstract: A human ECM-1 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for stimulating the differentiation in growth of osteoblasts and osteoclasts, which may be used to promote the healing of bone fractures and de novo bone formation, for osteoporosis, for and to promote angiogenesis. Antagonists to the polypeptide of the present invention are also disclosed which may be utilized to treat osteodystrophy, osteohypertrophy, osteoma, osteoblastoma and cancers. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: August 26, 2003
    Assignees: Unversity of Antwerp, Human Genome Sciences, Inc.
    Inventors: Jian Ni, Ping Feng, Patrick J. Dillon, Reiner L. Gentz, Joseph Merregaert, Patrick Smits
  • Galectin-11 polypeptides
    Patent number: 6605699
    Abstract: The present invention relates to galectin 11 proteins which are members of the galectin superfamily. In particular, the present invention relates to full-length polypeptides, fragments, and variants of galectin 11.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: August 12, 2003
    Assignees: Human Genome Sciences, Inc., La Jolla Institute for Allergy and Immunology
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen, Fu-Tong Liu
  • T1 receptor-like ligand II and uses thereof
    Patent number: 6605271
    Abstract: The present invention relates to a novel T1 Receptor (T1R)-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same. This invention further relates to pharmaceutical compositions and formulations comprising T1R-like ligand II. Also provided are methods of using T1R-like ligand II polynucleotides, polypeptides, antibodies or agonists/antagonists for therapeutic and diagnostic purposes. Diagnostic kits are further provided.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: August 12, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben
  • Keratinocyte growth factor-2
    Publication number: 20030129687
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Application
    Filed: February 15, 2002
    Publication date: July 10, 2003
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • T1 receptor-like ligand I
    Publication number: 20030129643
    Abstract: The present invention concerns a novel T1R-like ligand I protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand I protein. T1R-like ligand I polypeptides are also provided, as are recombinant vectors and host cells for expressing the same.
    Type: Application
    Filed: January 9, 2003
    Publication date: July 10, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen
  • CD33-like protein
    Patent number: 6590088
    Abstract: The present invention concerns a novel CD33-like protein. In particular, isolated nucleic acid molecules are provided encoding the CD33-like protein. Recombinant CD33-like polypeptides are also provided as are recombinant vectors and host cells. The invention further provides methods useful during tumor or inflammatory disease diagnosis or prognosis and therapeutic treatments targeting cells expressing CD33-like polypeptides.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: July 8, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Craig A. Rosen